Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.it.2021.02.006 http://scihub22266oqcxt.onion/10.1016/j.it.2021.02.006 33714688!ä!33714688 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33714688&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Trends+Immunol 2021 ; 42 (4): 293-311 Nephropedia Template TP {{tp|p=33714688|t=2021. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines |pdf=|usr=}}{{33714688}} gab.com Text Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines JO: Trends Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33714688 #FOAvip Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatment-induced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity. Twit Text FOAVip Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines ????Trends Immunol http://www.kidney.de/pget.php?&tw=1&pmid=33714688 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33714688 #FOAvip English Wikipedia <ref>{{Cite pmid|33714688}}</ref> Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines #MMPMID33714688 Kang JH; Bluestone JA; Young A Trends Immunol 2021[Apr]; 42 (4): 293-311 PMID33714688show ga Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatment-induced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity. |*Cytokines[MESH] |*Immune Checkpoint Inhibitors/adverse effects[MESH] |*Neoplasms/drug therapy[MESH] |Humans[MESH]Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Target(epmc).pdf DeepDyve Pubget Overpricing